Mea Biomarker Based Immunoassays Market Size and Share - Growth Analysis Report and Forecast Trends 2026-2030

The Middle East and Africa biomarker immunoassay market encompasses a range of diagnostic technologies including lateral flow immunoassays, enzyme-linked immunosorbent assays, and chemiluminescent immunoassays used across hospitals, diagnostic laboratories, and point-of-care settings. Valued at approximately $1.3 billion in 2025, the region's market reflects growing healthcare expenditure and expanding diagnostic capacity across diverse economic environments, from high-income Gulf states to lower-income sub-Saharan nations. Market development is shaped by varying levels of healthcare infrastructure, with significant opportunities emerging as countries invest in modernizing their diagnostic capabilities.

• •Encompasses lateral flow assays, laboratory-based immunoassay platforms, and emerging microfluidic technologies
• •Serves hospitals, clinical laboratories, and point-of-care settings across 50+ countries in the region
• •Growing adoption of rapid diagnostic tests for infectious disease screening and chronic disease monitoring

The high and persistent burden of infectious diseases including HIV, tuberculosis, viral hepatitis, and malaria continues to drive sustained demand for affordable immunoassay-based diagnostics that enable mass screening and continuous patient monitoring. Government and private sector investments in healthcare infrastructure are modernizing diagnostic capabilities, with particular emphasis on expanding access in rural and underserved communities where centralized laboratory services are limited. The cost-effectiveness, ease of use, and rapid turnaround time of immunoassay-based point-of-care tests compared to molecular diagnostics make them particularly well-suited to resource-constrained settings.

• •High prevalence of infectious diseases requiring widespread screening and ongoing therapeutic monitoring
• •Government initiatives and international health programs improving diagnostic access in underserved areas
• •Cost advantages and operational simplicity compared to molecular diagnostic alternatives

The market displays distinct regional patterns, with Gulf Cooperation Council countries driving laboratory-based immunoassay adoption through advanced healthcare infrastructure, while sub-Saharan African nations rely more heavily on point-of-care and lateral flow testing solutions that function without complex equipment or consistent electricity. Infectious disease testing represents the largest application segment, followed by cardiac markers and oncology applications, with the relative mix varying significantly by country based on disease prevalence and healthcare priorities. Saudi Arabia, South Africa, the United Arab Emirates, and Kenya collectively represent substantial market shares due to their larger healthcare budgets, population sizes, and active disease burden management programs.

• •Gulf states advancing laboratory immunoassay adoption while sub-Saharan Africa prioritizes point-of-care solutions
• •Infectious disease diagnostics comprising the dominant application category across most markets
• •Public health programs and diagnostic procurement tenders significantly influencing regional demand patterns

What are the recent trends and outlook?

Technological innovations in lateral flow assay design and microfluidic platforms are enabling more sensitive and quantitative immunoassay results at point-of-care settings, effectively expanding the range of clinical applications accessible without centralized laboratory infrastructure. Integration of digital connectivity features for result tracking, quality assurance, and artificial intelligence-assisted interpretation is beginning to transform traditional immunoassay workflows and improve diagnostic decision-making across the region. The market is positioned for sustained expansion as healthcare systems continue prioritizing preventive screening, early diagnosis, and decentralized diagnostic models aligned with regional public health objectives and universal health coverage goals.

• •Nanomaterial-enhanced electrochemical immunosensors improving assay sensitivity and detection limits
• •Multiplex immunoassay platforms gaining adoption for simultaneous detection of multiple biomarkers
• •Regional health security initiatives driving investment in domestic diagnostic manufacturing and technology transfer